We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Screening Tool Simplifies Serological Diagnosis of Neurocysticercosis

By LabMedica International staff writers
Posted on 24 Jul 2014
The availability of a rapid serological diagnosis that targets stage-specific antibodies for human cysticercosis is considered very helpful in control programs for estimating the sero-prevalence or burden of the disease in susceptible population groups.

Cysticercosis is a tissue infection caused by hatched oncospheres, a larval form of the pork tapeworm Taenia solium which parasitize the intestinal wall and circulate through the bloodstream, invade the nervous system and form cysts in the brain, leading to neurocysticercosis. More...


Medical parasitologists at the Leiden University Medical Center (The Netherlands) and their American colleagues developed a field-friendly screening tool to simplify serological diagnosis of neurocysticercosis. A total of 63 banked serum samples from patients with confirmed neurocysticercosis were used to validate the assay, and a total of 170 serum samples collected in regions where transmission of cysticercosis does not occur, were used to assess specificity. These samples consisted of a panel of 78 serum samples assembled from healthy residents of the USA and a panel of 92 serum samples from blood bank donors in the Netherlands.

The assay utilizes novel nano-sized up-converting phosphor (UCP) reporter particles in combination with a portable lightweight analyzer and detects antibodies in serum samples reactive with bacterial-expressed recombinant (r) T24H, a marker for detecting neurocysticercosis cases. Three sequential flow steps allow enrichment of antibodies on the Test (T) line and consecutive binding of protein-A coated UCP reporter particles. Antibody binding was determined by measuring 550-nm emission after excitation of the UCP label with a 980 nm infrared (IR) diode. Lateral flow (LF) strips were scanned using a multistrip scanner, modified Packard Fluorocount microplate reader (PerkinElmer; Waltham, MA, USA) and a customized ESEQuant lateral flow reader (LFR) (QIAGEN Lake Constance; Stockach, Germany).

The clinical sensitivity and specificity of the assay to detect cases of human neurocysticercosis with two or more viable brain cysts were 96% and 98%, respectively, using a sample set comprised of sera from 63 confirmed cases and 170 healthy parasite-naïve non-endemic controls. The evaluation of the new test with a set of clinical samples indicated excellent clinical parameters comparable to an enzyme-linked immunosorbent assay (ELISA). Application of new nano-sized UCP reporter label and a lightweight strip analyzer, both from easily accessible sources, demonstrated equivalent performance compared to previous studies. The study was published on July 3, 2014, in the journal Public Library of Science Neglected Tropical Diseases.


Related Links:

Leiden University Medical Center
PerkinElmer
QIAGEN



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.